Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels
Qrons Inc. (OTCQB:QRON) has filed an International Patent Application for its innovative Therapeutic Polypseudorotaxane Hydrogels, aimed at treating traumatic brain injuries and other nervous system conditions. Filed on March 12, 2023, the patent application number is PCT/IB2023/052368. The technology promises to support neuronal damage treatment and regeneration, with potential applications extending beyond traumatic brain injuries. CEO Jonah Meer emphasizes the significance of this filing in advancing their intellectual property and research initiatives. Qrons focuses on strategic partnerships to enhance its biotechnology developments, particularly in Israel, known for its biotech innovations.
- International Patent Application filed for Therapeutic Polypseudorotaxane Hydrogels, enhancing intellectual property.
- Potential applications extend beyond traumatic brain injuries, possibly addressing other nervous system conditions.
- Strategic partnerships sought with leading biotech innovators, enhancing development capabilities.
- None.
NEW YORK, NY / ACCESSWIRE / March 22, 2023 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform for the treatment of traumatic brain injuries (TBIs) and other nervous system pathologies, today announced that it has filed an International Patent Application at the International Bureau, for inventions of Therapeutic Polypseudorotaxane Hydrogels. This provides Qrons with the option to, in the future, seek protection for these inventions globally. This International Patent Application was filed on March 12, 2023, and was assigned application number PCT/IB2023/052368. It relates to uses of hydrogel compositions in the treatment of pathological central nervous system conditions such as traumatic injury or neurodegenerative disease, as well as manufacturing techniques for such compositions.
Jonah Meer, Qrons' co-founder and CEO, stated, " this filing advances our scientific discoveries not only for the treatment of neuronal damage and the inducement of neuronal regeneration but should have much broader applications beyond traumatic brain injuries to include other indications that we are currently researching. The filing continues the work of perfecting our IP. We are working and planning on the filing of additional patents as we broaden indications we believe our technology can address."
About Qrons Inc.
Headquartered in New York City, with research centered in Israel, Qrons is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases an enormous social and economic burden on society. Qrons' approach is to seek to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. Our search is focused on researchers based in Israel, a country which is world-renowned for biotech innovations For additional information, please visit www.qrons.com.
Forward Looking Statement
This press release includes "forward-looking statements." Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, future capital requirements, regulatory actions or delays and other factors that may cause actual results to be materially different from those described or anticipated by these forward-looking statements. The foregoing list of factors is not exclusive. For a more detailed discussion of these factors and risks, investors should review the Company's filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Contact:
Qrons Inc.
Jonah Meer, Chief Executive Officer
212-945-2080
SOURCE: Qrons Inc.
View source version on accesswire.com:
https://www.accesswire.com/745269/Qrons-files-US-National-Phase-of-its-Patent-Application-in-Furtherance-of-its-QS200-Product-Candidate-for-Therapeutic-Polypseudorotaxane-Hydrogels
FAQ
When did Qrons file its International Patent Application for Therapeutic Polypseudorotaxane Hydrogels?
What is the purpose of Qrons' Therapeutic Polypseudorotaxane Hydrogels?
What is the significance of the patent application number PCT/IB2023/052368 for Qrons?
How does Qrons plan to advance its research on Therapeutic Polypseudorotaxane Hydrogels?
What is the focus of Qrons' biotechnology development strategy?
